Sarepta shares early clinical data from siRNA treatments for rare diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
This stock's bull case is 'clearly stronger today than yesterday': analyst
March 27, 2026 7:00 PM EDTShares of one biotechnology name drew fresh attention after new clinical data strengthened the outlook for its siRNA-targeting programs, according to a note from Bernstein.
Analyst William Pickering said the early readouts by Sarepta Therapeutics in DM1 and FSHD showed encouraging signals despite limited disclosures.
He wrote that what they did present looks better than we had expected, noting that the... More
